Evidence map›Paper›PMID 37322408›Full record

ArticleBMC cancer2023

Molecular and clinical characterization of PTRF in glioma via 1,022 samples.

Si Sun, Changlin Yang, Kuanyu Wang, Ruoyu Huang, Ke-Nan Zhang, Yanwei Liu, Zhi Cao, Zheng Zhao, Tao Jiang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Si Sun *Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Changlin Yang *Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Kuanyu Wang *Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Ruoyu HuangBeijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Ke-Nan ZhangBeijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China.
Yanwei LiuDepartment of Radiotherapy, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Zhi CaoDepartment of Neurosurgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110032, China. cz057929@163.com.
Zheng ZhaoBeijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China. zhaozheng0503@ccmu.edu.cn.
Tao JiangBeijing Neurosurgical Institute, Capital Medical University, Beijing, 100070, China. taojiang1964@163.com.
Capital Medical University · CNBeijing Institute of Neurosurgery · CNBeijing Tongren Hospital · CNChina Medical University · CN

Funding

Beijing Hospitals Authority Youth Programme QML20230507Beijing Municipal Health Commission Fund 11000023T000002044300-5Brain Tumor Precision Diagnosis and Treatment and Translational Medicine Innovation Unit of Chinese Academy of Medical Sciences 2019-I2M-5-021
6 · The paper itself

Abstract

Polymerase I and transcript release factor (PTRF) plays a role in the regulation of gene expression and the release of RNA transcripts during transcription, which have been associated with various human diseases. However, the role of PTRF in glioma remains unclear. In this study, RNA sequencing (RNA-seq) data (n = 1022 cases) and whole-exome sequencing (WES) data (n = 286 cases) were used to characterize the PTRF expression features. Gene ontology (GO) functional enrichment analysis was used to assess the biological implication of changes in PTRF expression. As a result, the expression of PTRF was associated with malignant progression in gliomas. Meanwhile, somatic mutational profiles and copy number variations (CNV) revealed the glioma subtypes classified by PTRF expression showed distinct genomic alteration. Furthermore, GO functional enrichment analysis suggested that PTRF expression was associated with cell migration and angiogenesis, particularly during an immune response. Survival analysis confirmed that a high expression of PTRF is associated with a poor prognosis. In summary, PTRF may be a valuable factor for the diagnosis and treatment target of glioma.

Indexed as

DNA Copy Number VariationsGliomaCell Line, TumorHumansRNA-Binding ProteinsSurvival AnalysisCAVIN1 protein, humanRNA-Binding ProteinsGliomaImmune responsePrognosisPTRF

Identifiers

PMID37322408
PMCPMC10273567
OpenAlexW4380870402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.